Fosfomycin susceptibility on uropathogens in a tertiary care hospital, Mandya institute of medical sciences, Mandya

---

Author Details : Sharlee R*, Sumangala B

Volume : 6, Issue : 1, Year : 2019

Article Page : 15-17

https://doi.org/10.18231/2394-5478.2019.0004

Suggest article by email

Get Permission

---

Abstract

Introduction: Urinary tract infection (UTI) is an important cause of illness in humans with emergence of multidrug resistance. Fosfomycin remains to be effective against MDR uropathogens. We evaluated susceptibility of Fosfomycin against uropathoges.
Materials and Methods: A prospective study was conducted for a period of 6 months in a tertiary care hospital MIMS, Mandya. Significant bacterial growth were identified in urine samples and processed accordingly. Fosfomycin susceptibility was performed by Kirby-Bauer disc diffusion method along with other drugs advised as per CLSI guidelines.
Results: A total of 893 urine samples were received, 150 samples showed significant growth of one or two organisms, yielding a sum of 162 isolates. Out of 162 isolates with significant growth of organisms, majority were Gram negative bacilli (GNB) accounting for 63.6% (103 isolates) followed by Gram positive cocci (GPC) 36.4% (59 isolates).
Out of 103 GNB, ESBL producer were 25.2%, Carbapenamase producer were 1.9%, Amp C were 6.8%, ESBL+ Carbapenamase were 4.9%, Amp C + Carbapenemase were 2.9% and 58.3% were non ESBL, Carbapenamase and AmpC producer.
Out of 162 isolates, 156(96.3 %) were sensitive to Fosfomycin and 6 (3.7%) were resistant to Fosfomycin.
Conclusions: Fosfomycin is effective against MDR, ESBL, AmpC and Carbapenamse producing uropthaogens. It is an effective, convenient and safe drug for treating the patients of all age group and pregnant mothers with uncomplicated UTIs.

Keywords: UTI, MDR, AmpC, ESBL, GPC, GNB.

How to cite : Sharlee R, Sumangala B, Fosfomycin susceptibility on uropathogens in a tertiary care hospital, Mandya institute of medical sciences, Mandya. Indian J Microbiol Res 2019;6(1):15-17

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.